Ocuphire Pharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-02-01
- Employees
- 14
- Market Cap
- $31.9M
- Website
- http://www.ocuphire.com
- Introduction
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
- Conditions
- Presbyopia
- Interventions
- Drug: 0.75% phentolamine ophthalmic solutionDrug: Placebo
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 545
- Registration Number
- NCT06542497
- Locations
- 🇺🇸
United States, San Antonio, Texas, United States
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
- Conditions
- Mesopic VisionNight Vision Loss
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06349759
- Locations
- 🇺🇸
United States, Tampa, Florida, United States
🇺🇸United States Rowland Heights, Rowland Heights, California, United States
🇺🇸United States, California, Newport Beach, California, United States
Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia
- Conditions
- Presbyopia
- Interventions
- Drug: Phentolamine Opthalmic Solution 0.75%Other: PlaceboDrug: Low dose pilocarpineOther: Low dose pilocarpine vehicle
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT05646719
- Locations
- 🇺🇸
Houston, TX, Houston, Texas, United States
🇺🇸San Antonio, TX, San Antonio, Texas, United States
🇺🇸Phoenix, AZ, Phoenix, Arizona, United States
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
- Conditions
- MydriasisDilation
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05223478
- Locations
- 🇺🇸
Clinical Site 2, Athens, Ohio, United States
🇺🇸Clinical Site 1, Longwood, Florida, United States
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
- Conditions
- MydriasisDilation
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 368
- Registration Number
- NCT05134974
- Locations
- 🇺🇸
Clinical Site 5, Pittsburg, Kansas, United States
🇺🇸Clinical Site 10, Newport Beach, California, United States
🇺🇸Clinical Site 9, Delray Beach, Florida, United States
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
- Conditions
- Diabetic RetinopathyDiabetic Macular EdemaNPDR - Non Proliferative Diabetic RetinopathyPDR - Proliferative Diabetic Retinopathy
- Interventions
- Drug: APX3330Drug: Placebo
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04692688
- Locations
- 🇺🇸
Clinical Site 11, Palm Desert, California, United States
🇺🇸Clinical Site 5, Beverly Hills, California, United States
🇺🇸Clinical Site 9, Phoenix, Arizona, United States
Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia
- Conditions
- Presbyopia
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT04675151
- Locations
- 🇺🇸
Clinical Site 18, Saint Louis, Missouri, United States
🇺🇸Clinical Site 12, Laguna Hills, California, United States
🇺🇸Clinical Site 3, Pittsburg, Kansas, United States
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
- Conditions
- Dim Light Vision Disturbances
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04638660
- Locations
- 🇺🇸
Clinical Site 13, Pittsburg, Kansas, United States
🇺🇸Clinical Site 1, Petaluma, California, United States
🇺🇸Clinical Site 19, Ogden, Utah, United States
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis
- Conditions
- MydriasisDilation
- Interventions
- Drug: Phentolamine Ophthalmic Solution 0.75%Other: Phentolamine Ophthalmic Solution Vehicle (Placebo)
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT04620213
- Locations
- 🇺🇸
Clinical Site 7, Pittsburg, Kansas, United States
🇺🇸Clinical Site 3, Shawnee Mission, Kansas, United States
🇺🇸Clinical Site 11, Newport Beach, California, United States
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
- Conditions
- MydriasisDilation
- Interventions
- Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)Drug: Phentolamine Mesylate Ophthalmic Solution 1%
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04024891
- Locations
- 🇺🇸
West Bay Eye Associates, Warwick, Rhode Island, United States
🇺🇸Kannar Eye Care, Pittsburg, Kansas, United States
🇺🇸Athens Eye Care, Athens, Ohio, United States